Zanubrutinib

Active substance
Zanubrutinib
Domain
Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Aggressive non-Hodgkin's lymphoma
Extended indication
Mantelcel non-hodgkin lymfoom Waldenström's macroglobulinaemia (WM) Chronische Lymfatische Leukemie (CLL)

1. Product

Proprietary name
BGB-3111
Manufacturer
BeiGene
Mechanism of action
Tyrosine kinase inhibitor
Route of administration
Oral
Therapeutical formulation
Capsule
Budgetting framework
Intermural (MSZ)

2. Registration

Registration route
Centralised (EMA)
Orphan drug
Yes
Registration phase
Clinical trials

3. Therapeutic value

Current treatment options
Zal competitief zijn met ibrutinib.
Therapeutic value
No judgement
Duration of treatment
Not found

4. Expected patient volume per year

Patient volume

27 - 79

Market share is generally not included unless otherwise stated.

References
Pakketadvies ibrutinib
Additional comments
De verwachting is dat zanubrutinib de concurrentie aan zal gaan met ibrutinib. De inschatting van het patiëntvolume in het ''pakketadvies ibrutinib'' bij patiënten met CLL betrof 27 tot 79 mogelijke patiënten die in aanmerking komen.

5. Expected cost per patient per year

Additional comments
Huidige Lijstprijs ibrutinib x Maximaal gebruik per jaar: €69.839. Dit betreft alleen Ibrutinib. Voor de indicatie 1e lijns Chronische lymfatische leukemie (CLL) wordt onderhandeld over een financieel arrangement en zit het geneesmiddel in de sluis.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
Yes
Indication extensions
B-cell lymphoma; Waldenstrom's macroglobulinaemia
References
adisinsight
Additional comments
Lopende fase 3 studies.

9. Other information

There is currently no futher information available.